Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
28 hedge funds and large institutions have $772K invested in Navidea Biopharmaceuticals Inc. in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 6 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
104% more capital invested
Capital invested by funds: $379K → $772K (+$393K)
25% more call options, than puts
Call options by funds: $142K | Put options by funds: $114K
3% less funds holding
Funds holding: 29 → 28 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$11.1K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$8.39K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$5.65K |
| 4 |
JP Morgan Chase
New York
|
+$5.14K |
| 5 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$2.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 2 |
VF
Virtu Financial
New York
|
-$13K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.04K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| – | -$1.73K | -2,000 | Closed |
|
|
HIIFS
27
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| – | +$5 | +6 | New |
|
|
LTFS
28
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$5 | +6 | New |
|
|
GI
29
Gradient Investments
Arden Hills,
Minnesota
| – | +$27 | +31 | New |
|
|
TI
30
tru Independence
Portland,
Oregon
| – | +$86 | +100 | New |
|
NAVB Hedge Fund Activity: Q4 2019 in Review
28 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2019, worth a combined $772K — up 104% from $379K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NAVB and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 7 added.
The largest buyer was Allred Capital Management, adding an estimated $11.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $20K sold.
- 28 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2019, down from 29 in Q3 2019.
- Funds reported $772K of Navidea Biopharmaceuticals Inc. stock for Q4 2019, up 104% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2019 and 6 closed out, a net change of -1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2019 was Allred Capital Management, an estimated $11.1K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2019 was Citadel Advisors, an estimated $20K sold.
Based on aggregated 13F filings for Q4 2019.